Skip to main content

ORBIMED ADVISORS LLC

Position in CCCC — C4 Therapeutics, Inc.

CIK 1055951 New York, NY

Position in CCCC

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$2,252,208
-$431,154 QoQ
Shares Held
856,353
-39.0% QoQ
Ownership
0.696%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority Sole 46% Shared 0% None 54%

Common Shares in CCCC Over Time

Shares Held

Position Value (USD)

Derivatives in CCCC

reported options exposure · as of Dec 31, 2024
CallValue
$540,000
CallShares
150,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

ORBIMED ADVISORS LLC holds $3,639,640,835 across 90 Biotechnology names.

# Ticker Company Shares Value (USD) Open

All Filings in CCCC

Export CSV
10 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $2,252,208 856,353
2025-12-31 $2,683,362 1,404,902
2025-09-30 $11,622,024 5,235,146
2025-06-30 $9,767,329 6,830,300
2025-03-31 $10,928,480 6,830,300
2024-12-31 $15,760,440 4,377,900
2024-12-31 $540,000 150,000
2024-09-30 $855,000 150,000
2024-09-30 $24,954,030 4,377,900
2024-06-30 $6,990,327 1,513,058